The present invention relates to the technical field of medical devices, in particular to a drug coating, a drug-coated balloon and a preparation method thereof. The drug coating comprises a drug active coating and a positively-charged hydrophobic modified layer which are sequentially attached to the surface of a substrate. By providing the positively charged hydrophobic modified layer comprising the positively-charged modified substance and the hydrophobic substance, the entire surface of the drug coating is given positive electric charge and hydrophobic property. Such positive electric charge characteristics make the drug coating can be strongly combined with the negatively-charged inner wall of blood vessels, so that the drug coating can be permanently adsorbed on the inner wall of blood vessels. The combination of positive electric charge characteristics and hydrophobic property can effectively resist the influence of blood flow on the erosion of drug coating during transportation.

Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.

A CO.sub.2 processed sheet structure comprising ECM derived from mammalian submucosa tissue, which can be formed into a pouch configured to encase a medical device.

The invention discloses an absorbable iron-based alloy stent, comprising an iron-based alloy substrate and a degradable polyester in contact with the surface of the substrate, in which the degradable polyester has a weight average molecular weight of between 20,000 and 1,000,000 and a polydispersity index of between 1.2 and 30. With the degradable polyester, the iron-based alloy is capable of corroding rapidly and controllably within a predetermined period. Following implantation into the human body, the degradable stent serves as a mechanical support at early stage, then gradually degrading and being metabolized and absorbed by the human body. During the process of degradation, minimal or no solid product is produced. Ultimately, the configuration of the lumen with an implanted stent as well as the systolic and diastolic functions thereof return to their natural states.

Vascular grafts for treating, reconstructing and replacing damaged or diseased cardiovascular vessels that are formed from decellularized extracellular matrix (ECM). The vascular grafts include structural reinforcement means, such as a strand of wound biodegradable polymeric material disposed proximate the outer surface of the graft.

There is provided an absorbent system for wound care products having a liquid-absorbing, wound-contacting, lower layer and a more highly absorbent upper layer in liquid communication with said lower layer. Liquid communication may be provided by pores running between the layers. The dressing may include antimicrobial agents, agents to promote healing and other functional agents.

The present invention relates to an implant having a surface comprising a coating on at least a portion of the surface of the implant, wherein the coating comprises at least two coating layers of bioactive compounds adjacent to each other, obtainable in a process comprising the following steps: providing an implant with a surface, providing a first suspension comprising at least one first bioactive compound in a first solvent, wherein the first bioactive compound is non-soluble or partially soluble in the first solvent, applying said first suspension comprising the at least one first bioactive compound onto at least a part of the implant surface forming a first coating layer; drying the first coating layer, providing a second solution comprising at least one second bioactive compound in a second solvent, wherein the second bioactive compound is soluble or readily soluble in the second solvent; applying said second solution comprising the at least one second bioactive compound onto the first coating layer forming a second coating layer, and drying the second coating layer.

Aortic valve stenosis (AS) also called also called Calcific aortic valve disease (CAVD), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that EZH2 inhibition with GSK-126 and GSK-343 directly regulates monocyte and M1 toward M2 macrophage differentiation, reducing VIC deactivation and osteoblastic transition and thus represents an attractive therapeutic target to prevent AS progression. Therefore, the present invention relates to use of EZH2 inhibitors for the treatment of aortic valve stenosis.

A drug delivery device includes a reservoir configured to receive a fluid, a cannula in fluid communication with the reservoir, with the cannula configured to be inserted into subcutaneous tissue or muscle tissue of a patient, and a pump configured to deliver a fluid from the reservoir to the cannula. The cannula includes a bioactive agent configured to cause a tissue response to decrease a pressure required to deliver fluid from the reservoir. The tissue response can include vasodilation, vasoconstriction, increased tissue permeability, increased flow of interstitial fluid or enzymatic deterioration of extracellular matrix.

The present disclosure teaches the treatment or prophylaxis of infection by a microorganism including a fungus or bacterium which is infecting or colonizing an in vivo tissue, surface or membrane. The method comprising administering to the subject with the infection or directly to the site of infection a plant-derived defensin or a functional variant or derivative thereof.